Open AccessAdvances in Immunotherapy of Malignant Pleural Mesothelioma
Author(s) -
Dongying Liao,
Yongchao Yu,
Qingyun Mei,
Ziwei Wang,
Xiaojiang Li,
Yulin Jia,
Fanming Kong
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s317434
Subject(s) - nivolumab , medicine , ipilimumab , immunotherapy , oncology , mesothelioma , cancer , pathology
Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from pleural mesothelial cells, which is associated with dismal prognostic outcome. According to CheckMate-743 results, nivolumab plus ipilimumab has been approved to treat the unresectable MPM in treatment-naive patients as a first-line therapy by the FDA in October 2020. Immunotherapy is expected to be the best choice for MPM treatment. In the following article, the past treatment plan and the progress of immunotherapy for MPM will be reviewed.